UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

1 Dec 2022

UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care

Read More
22 Nov 2022

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Read More
14 Nov 2022

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Read More
10 Nov 2022

Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis

Read More
8 Nov 2022

UCB Reinforces Commitment to Rheumatology with 15 Abstracts including New Late-Breaking Data at ACR Convergence 2022

Read More
13 Oct 2022

UCB announces positive preliminary results for major brivaracetam (Briviact[®]) study in Asia

Read More

Stay up-to-date on the latest news and information from UCB